CYC Cyclopharm Limited
Healthcare · Medical Devices
· website
· 104 employees
$0.44
52wk 0.44 – 1.29
Overall
36.5
Value
95.9
Growth
0.0
Health
68.3
Quality
0.0
Momentum
0.0
Dividend
—
Price
About Cyclopharm Limited
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is based in Kingsgrove, Australia.
Price analytics
Returns
| 1 day | -2.2% |
| 1 week | -2.2% |
| 1 month | -13.7% |
| 3 months | -4.3% |
| 6 months | -46.0% |
| 1 year | -49.4% |
| 3 years | -80.4% |
Risk
| Volatility (1y ann.) | 84.7% |
| Beta vs ASX 200 | 0.52 |
| Sharpe (1y) | -0.45 |
| VaR 95% (1-day) | -6.7% |
| Max drawdown (1y) | -64.2% |
| Off 1-year high | -64.2% |
Technicals
| RSI(14) | 12 OS |
| vs 50DMA | -13.4% |
| vs 200DMA | -37.4% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
95.9
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
87
Price / Sales
91
Growth
0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
0
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
68.3
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
98
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
0.0
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
0
Position in 52-week range
0
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$55.32M
P/E (trailing)
—
P/E (forward)
-4.83
EPS (trailing)
-0.16
Dividend yield
—
Payout ratio
0.0%
Beta
0.59
EV / EBITDA
-3.12
Price / Book
1.74
ROE
-53.9%
Operating margin
-48.0%
Net margin
-53.2%
Total cash
$12.25M
Total debt
$7.80M
Current ratio
3.37
Debt / Equity
0.24
Free cash flow
$-9.63M
Avg volume
64,599
Latest annual results
(FY ending 31 Dec 2025)
- Revenue$16.69M
- Gross profit$2.22M
- Operating income-$33.82M
- Net income-$17.22M
- Diluted EPS-0.16
- Free cash flow-$19.44M
- Net debt$1.11M